Browsing by Author "Ayyildiz, O"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
Item Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experienceGemici, A; Aydogdu, I; Terzi, H; Sencan, M; Aslan, A; Kaya, AH; Dal, MS; Akay, MO; Dogu, MH; Ayyildiz, O; Sahin, F; Cagliyan, GA; Yilmaz, M; Gokgoz, Z; Bilen, Y; Demir, C; Sevindik, OG; Korkmaz, S; Eser, B; Altuntas, FNodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37.5years (18-70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow-up was 46months. During follow-up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses.Item Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 studyAkpinar, S; Tekgunduz, E; Esen, R; Yilmaz, M; Karakus, V; Vural, F; Gediz, F; Aydogdu, I; Kaynar, L; Goker, H; Kelkitli, E; Ayyildiz, O; Demirkan, FTo understand who uses social media and how often they do so, we examined the personality traits that predict frequency of using a set of 10 different types of social media (e.g., social networks, blogs, virtual worlds). Using survey data collected from two large-scale samples of young adults (Exploratory Study 1 N = 1586, Confirmatory Study 2 N =1432), we conducted direct replications of our findings to test whether the observed relationships between social media use and personality traits were reliable. Our replicated findings reveal that sex, age and extraversion are reliable predictors of several types of social media use (e.g., Facebook, Messaging Platforms, Online Forums), while other traits (e.g., agreeableness, Machiavellianism) showed unreliable associations. Our findings also reveal dimensions of multiplatform social media use that categorize the media ecologies of young adults and show significant associations with individual difference measures. (C) 2020 Published by Elsevier Inc.Item Evolution of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in turkey: a multicenter retrospective analysisKaradag, FK; Yenerel, MN; Yilmaz, M; Uskudar, H; Ozkocaman, V; Tuglular, TF; Erdem, F; Unal, A; Ayyildiz, O; Ozet, G; Comert, M; Kaya, E; Ayer, M; Salim, O; Guvenc, B; Ozdogu, H; Mehtap, O; Sonmez, M; Guler, N; Hacioglu, S; Aydogdu, I; Bektas, O; Toprak, SK; Kaynar, L; Yagci, M; Aksu, S; Tombak, A; Karakus, V; Yavasoglu, I; Onec, B; Ozcan, MA; Undar, L; Ali, R; Ilhan, O; Saydam, G; Sahin, FParoxysmal nocturnal hemoglobinuria (PNH) is a rare X-linked genetic disorder. On the contrary to its name, it is a multisystemic disease and various symptoms other than hemoglobinuria could be occurred. It could be life threatening especially because of thromboembolic events. In the last decade, a terminal complement inhibition with eculizumab approved with promising results for PNH patients. We conducted this study to evaluate the long term experience of eculizumab therapy from Turkey for the first time. Our cohort included 138 patients with PNH treated with eculizumab between January 2008 and December 2018 at 28 centers in Turkey. Laboratory and clinical findings at the time of diagnosis and after eculizumab therapy were recorded retrospectively. The median age was 39 (range 18-84) years and median granulocyte PNH clone size was 74% (range 3.06-99.84%) at the time of diagnosis. PNH with bone marrow failure syndrome was detected in 49 patients and the rest of 89 patients had classical PNH. Overall 45 patients (32.6%) had a history of any prior thrombotic event before eculizumab therapy and only 2 thrombotic events were reported during the study period. Most common symptoms are fatigue (75.3%), hemoglobinuria (18.1%), abdominal pain (15.2%) and dysphagia (7.9%). Although PNH is commonly related with coombs negativity, we detected coombs positivity in 2.17% of patients. Seven months after the therapy, increased hemoglobin level was seen and remarkably improvement of lactate dehydrogenase level during the treatment was occurred. In addition to previous studies, our real life data support that eculizumab is well tolerated with no serious adverse events and improves the PNH related findings.Item Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from TurkeyKaradag, FK; Yenerel, MN; Mehmet, Y; Teke, HU; Ozkocaman, V; Tuglular, T; Erdem, F; Unal, A; Ayyildiz, O; Ozet, G; Ozkan, M; Kaya, E; Ayer, M; Salim, O; Güvenç, B; Ozdogu, H; Mehtap, Ö; Sönmez, M; Güler, N; Hacioglu, SK; Aydogdu, I; Bektas, O; Toprak, SK; Kaynar, L; Yagci, M; Aksu, S; Tombak, A; Karakus, V; Yavasoglu, I; Öneç, B; Özcan, MA; Ündar, L; Ali, R; Ustun, C; Ilhan, O; Saydam, G; Sahin, F